High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications

Rajkumar, 2015, Smoldering multiple myeloma, Blood, 125, 3069, 10.1182/blood-2014-09-568899 Kyle, 2007, Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma, N Engl J Med, 356, 2582, 10.1056/NEJMoa070389 Landgren, 2017, Shall we treat smoldering multiple myeloma in the near future?, Hematol Am Soc Hematology Educ Progr, 2017, 194, 10.1182/asheducation-2017.1.194 Mateos, 2013, Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma, N Engl J Med, 369, 438, 10.1056/NEJMoa1300439 Kyle, 1980, Smoldering multiple myeloma, N Engl J Med, 302, 1347, 10.1056/NEJM198006123022405 International Myeloma Working, 2003, Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group, Br J Haematol, 121, 749, 10.1046/j.1365-2141.2003.04355.x Larsen, 2013, Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma, Leukemia, 27, 941, 10.1038/leu.2012.296 Kastritis, 2013, Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease, Leukemia, 27, 947, 10.1038/leu.2012.309 Hillengass, 2010, Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma, J Clin Oncol, 28, 1606, 10.1200/JCO.2009.25.5356 Kastritis, 2014, The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma, Leukemia, 28, 2402, 10.1038/leu.2014.230 Rajkumar, 2014, International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol, 15, e538, 10.1016/S1470-2045(14)70442-5 Zamagni, 2016, 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease, Leukemia, 30, 417, 10.1038/leu.2015.291 Sørrig, 2016, Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study, Eur J Haematol, 97, 303, 10.1111/ejh.12728 Wu, 2018, Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling, Blood Adv., 2, 1470, 10.1182/bloodadvances.2018016998 Perez-Persona, 2007, New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells, Blood, 110, 2586, 10.1182/blood-2007-05-088443 Dispenzieri, 2008, Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma, Blood, 111, 785, 10.1182/blood-2007-08-108357 Lakshman, 2018, Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria, Blood Canc J, 8, 59, 10.1038/s41408-018-0077-4 San Miguel, 2019, Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria, J Clin Oncol, 37, 8000, 10.1200/JCO.2019.37.15_suppl.8000 Cherry, 2013, Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study, Leuk Lymphoma, 54, 2215, 10.3109/10428194.2013.764419 Dhodapkar, 2014, Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120), Blood, 123, 78, 10.1182/blood-2013-07-515239 Rosinol, 2003, Smoldering multiple myeloma: natural history and recognition of an evolving type, Br J Haematol, 123, 631, 10.1046/j.1365-2141.2003.04654.x Fernandez de Larrea, 2018, Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression, Leukemia, 32, 1427, 10.1038/s41375-018-0013-4 Lakshman, 2018, Response to 'Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression', Leukemia, 32, 2083, 10.1038/s41375-018-0155-4 Ravi, 2016, Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma, Blood Canc J, 6, e454, 10.1038/bcj.2016.65 Rosinol, 2005, Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma, Br J Haematol, 130, 729, 10.1111/j.1365-2141.2005.05673.x Dispenzieri, 2014, S0120 G.E.M.S.: genomics encounters MGUS and SMM, Blood, 123, 4, 10.1182/blood-2013-11-535575 Rajkumar, 2013, Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma, Leukemia, 27, 1738, 10.1038/leu.2013.86 Neben, 2013, Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load, J Clin Oncol, 31, 4325, 10.1200/JCO.2012.48.4923 Bianchi, 2013, High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma, Leukemia, 27, 680, 10.1038/leu.2012.237 Gonsalves, 2017, Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression, Leukemia, 31, 130, 10.1038/leu.2016.205 Merz, 2014, Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma, Leukemia, 28, 1902, 10.1038/leu.2014.75 Hjorth, 1993, Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden, Eur J Haematol, 50, 95, 10.1111/j.1600-0609.1993.tb00148.x Riccardi, 2000, Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative group of study and treatment of multiple myeloma, Br J Canc, 82, 1254, 10.1054/bjoc.1999.1087 Witzig, 2013, A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma, Leukemia, 27, 220, 10.1038/leu.2012.236 Mahesh, 2013, Treatment for high-risk smoldering myeloma, N Engl J Med, 369, 1764 Munshi, 2017, Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis, JAMA Oncol, 3, 28, 10.1001/jamaoncol.2016.3160 Landgren, 2016, Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis, Bone Marrow Transplant, 51, 1565, 10.1038/bmt.2016.222 Korde, 2015, Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma, JAMA Oncol, 1, 746, 10.1001/jamaoncol.2015.2010 Mailankody, 2017, Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma, Blood Adv, 1, 1911, 10.1182/bloodadvances.2017005934 Mateos, 2019, Curative strategy (Gem-Cesar) for high-risk smoldering myeloma: carfilzomib, lenalidomide and dexamethasone (Krd) as induction followed by hdt-Asct, consolidation with Krd and maintenance with Rd: S871, HemaSphere, 3, 390, 10.1097/01.HS9.0000561764.53887.c0 Mateos, 2018, Curativestategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and maintenance with Rd, Blood, 132, 2142, 10.1182/blood-2018-99-112656 Bustoros, 2018, Phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma, Blood, 132, 804, 10.1182/blood-2018-99-117871 Liu, 2018, Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma, Blood, 132, 154, 10.1182/blood-2018-154 Mailankody, 2019, Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study, J Clin Oncol, 37, 8051, 10.1200/JCO.2019.37.15_suppl.8051 Lonial, 2019, Randomized trial of lenalidomide versus observation in smoldering multiple myeloma, J Clin Oncol, JCO1901740, 10.1200/JCO.19.01740 Jagannath, 2018, Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study, Br J Haematol, 182, 495, 10.1111/bjh.15384 Hofmeister, 2017, Daratumumab monotherapy for patients with intermediate or high-risk smoldering multiple myeloma (SMM): centaurus, a randomized, open-label, multicenter phase 2 study, Blood, 130, 510 Landgren, 2018, Updated results from the phase 2 centaurus study of daratumumab (DARA) monotherapy in patients with intermediate-risk or high-risk smoldering multiple myeloma (SMM), Blood, 132, 1994, 10.1182/blood-2018-99-113467 Manasanch, 2019, A multicenter phase II single arm trial of isatuximab in patients with high risk smoldering multiple myeloma (HRSMM), Blood, 134, 3116, 10.1182/blood-2019-123205 Dhodapkar, 2015, Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy, Blood, 126, 2475, 10.1182/blood-2015-03-632919 Manasanch, 2019, A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis, Blood Adv, 3, 2400, 10.1182/bloodadvances.2019000300 Ayers, 2017, IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade, J Clin Invest, 127, 2930, 10.1172/JCI91190 Gormley, 2018, Immunotherapy combinations in multiple myeloma - known unknowns, N Engl J Med, 379, 1791, 10.1056/NEJMp1803602 Brighton, 2019, Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma, Clin Canc Res, 25, 3772, 10.1158/1078-0432.CCR-18-3470 2003, Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group, Br J Haematol, 121, 749, 10.1046/j.1365-2141.2003.04355.x Atrash, 2018, Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma, Blood Canc J, 8, 107, 10.1038/s41408-018-0144-x Khan, 2015, Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120), Haematologica, 100, 1214, 10.3324/haematol.2015.124651 Siontis, 2015, Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy, Blood Canc J, 5, e364, 10.1038/bcj.2015.87 Mateos, 2017, Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma, N Engl J Med, 378, 518, 10.1056/NEJMoa1714678 Kumar, 2016, International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, Lancet Oncol, 17, e328, 10.1016/S1470-2045(16)30206-6